With aging, physiological changes occur that affect the pharmacokinetics and pharmacodynamics of drugs. Renal and hepatic impairment, multimorbidity, and polypharmacy increase the risk of adverse reactions in elderly patients. These factors complicate safe drug use and highlight the importance of pharmacovigilance. Flecainide is a class IC antiarrhythmic medication with a narrow therapeutic index. It is frequently used for the treatment of supraventricular arrhythmias. Different dosage forms (immediate-release (IR) and extended-release (ER)) may differently influence blood plasma concentrations, pharmacodynamic effects, and safety, particularly in elderly patients. The objective: to evaluate the impact of flecainide dosage form (IR and ER) on pharmacokinetic parameters, safety outcomes, and efficacy based on published studies. Materials and methods. A narrative review of published clinical and pharmacokinetic studies was conducted, focusing on peak plasma concentration (Cmax), time to reach Cmax (tmax), area under the curve (AUC), elimination half-life (t½), concentration fluctuations, electrocardiographic effects, and safety profiles of medications with IR and ER flecainide formulations. Results. ER formulations are characterized by lower peak concentrations (Cmax), smoother diurnal fluctuations, and a more stable pharmacokinetic profile compared with IR formulations, while providing a comparable systemic exposure. Clinical studies indicate a reduction in peak QRS widening on electrocardiogram with ER administration, suggesting a lower risk of concentration-dependent toxicity. Patients with renal or hepatic failure, chronic heart failure, or carriers of CYP2D6 polymorphic alleles are at increased risk of drug accumulation. Conclusions. ER flecainide formulations reduce blood plasma concentration fluctuations, potentially decreasing peak-related toxicity and providing safer antiarrhythmic therapy, particularly in patients with reduced clearance, including the elderly.